# Botox Cosmetic (onabotulinumtoxina) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/onabotulinumtoxina

> The next catalyst for Botox Cosmetic (onabotulinumtoxina), sponsored by AbbVie Inc. (ABBV), is its primary completion, June 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Botox Cosmetic (onabotulinumtoxina) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [Forehead Lines](https://sec-api.dev/indications/forehead-lines), Upper Facial Lines |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### July 8, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA103000 SUPPL-5315 (Efficacy): submission_status AP, submission_status_date 20200708, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22

### February 9, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA103000 SUPPL-5318 (Efficacy): submission_status AP, submission_status_date 20210209, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22

### July 28, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA103000 SUPPL-5320 (Efficacy): submission_status AP, submission_status_date 20210728, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22

### August 11, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA103000 SUPPL-5325 (Efficacy): submission_status AP, submission_status_date 20230811, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22

### October 18, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA103000 SUPPL-5331 (Efficacy): submission_status AP, submission_status_date 20241018, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22

### April 3, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Forehead Lines.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06794866 (A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-03 (ACTUAL); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06794866

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Upper Facial Lines; Glabellar Lines.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07871513 (A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07871513

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Upper Facial Lines; Glabellar Lines.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07871513 (A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07871513

## Same indication

- [AGN-151586](https://sec-api.dev/pdufa/agn-151586) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/onabotulinumtoxina.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Botox Cosmetic (onabotulinumtoxina) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/onabotulinumtoxina

```bibtex
@misc{secapidev_pdufa_onabotulinumtoxina_20261116,
  title        = {Botox Cosmetic (onabotulinumtoxina) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/onabotulinumtoxina}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_onabotulinumtoxina_20261116","title":"Botox Cosmetic (onabotulinumtoxina) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/onabotulinumtoxina","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
